Merck Acquires CN201 Therapy for $1.3 Billion

Aug 9, 2024, 12:11 PM

Merck has announced its acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical. The deal involves an upfront payment of $700 million in cash, with potential earnouts of up to $600 million, bringing the total transaction value to $1.3 billion. CN201 is a next-generation CD3xCD19 bispecific antibody that aims to enhance Merck’s pipeline with potential applications in treating B-cell malignancies and autoimmune diseases. This strategic acquisition highlights Merck's commitment to expanding its capabilities in immune disease therapeutics.